The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR

Yanhua Zhou; Qiulu Zhong; Dongning Huang; Li Qin; Jian Huang; Chunhui Wang; Binglin Chen; Menghua Chen; Yihe Li; Wenqi Liu

doi:doi:10.18632/aging.204148

← Back

Research Paper Volume 14, Issue 12 pp 5223—5232

The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR

Figure 3. The subgroups analysis of EGFR mutation between two groups. (A) 1-year OS rates of EGFR mutation between two groups (P>0.05). (B) 1-year PFS_first rates of EGFR mutation between two groups (P>0.05).